Saturday 17 October 2026
Export HSIC’s income statement to Excel — free account
Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024. In the quarter to June 2026, revenue grew 6.73%, EPS grew 16.9%, free cash flow grew 140.9% and total debt rose 15.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
86.38
0.61
−0.70%
Follow HSIC
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 55.94 | 51.20 | 49.07 | 56.58 | 41.85 | 60.70 | 64.75 | 60.01 | 63.67 | 60.56 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 71.76 | 73.33 | 71.65 | 72.81 | 73.99 | 83.45 | 92.68 | 89.72 | 82.63 | 82.49 | |||||
| People | |||||||||||||||
| People | Employees | 21,000 | 22,000 | 18,000 | 19,000 | 19,000 | 21,600 | 22,000 | 25,000 | 25,000 | 25,000 | ||||
| Revenue/emp, $m | 0.55 | 0.40 | 0.52 | 0.53 | 0.53 | 0.57 | 0.57 | 0.49 | 0.51 | 0.53 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 11,572 | 8,883 | 9,418 | 9,986 | 10,119 | 12,401 | 12,647 | 12,339 | 12,673 | 13,184 | ||||
| Gross margin, % | 27.88 | 30.92 | 30.91 | 30.95 | 27.83 | 29.63 | 30.29 | 31.28 | 31.69 | 31.14 | |||||
| EBT | 756 | 630 | 537 | 680 | 500 | 831 | 721 | 542 | 513 | 533 | |||||
| EBT margin, % | 6.53 | 7.09 | 5.70 | 6.81 | 4.94 | 6.70 | 5.70 | 4.39 | 4.05 | 4.04 | |||||
| Net income | 556 | 459 | 562 | 719 | 420 | 660 | 566 | 436 | 398 | 419 | |||||
| Depreciation | 170 | 134 | 144 | 185 | 186 | 210 | 212 | 275 | 309 | 311 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 71.59 | 56.66 | 61.69 | 67.56 | 71.01 | 88.52 | 92.95 | 94.47 | 99.95 | 109.13 | ||||
| Earnings | 3.14 | 2.59 | 3.51 | 4.70 | 2.83 | 4.51 | 3.95 | 3.18 | 3.07 | 3.29 | |||||
| Cash flow | 3.98 | 3.48 | 4.49 | 4.43 | 4.20 | 5.07 | 4.42 | 3.83 | 6.69 | 5.89 | |||||
| Capex | (0.43) | (0.40) | (0.47) | (0.52) | (0.34) | (0.56) | (0.71) | (1.13) | (1.17) | (1.15) | |||||
| Free cash flow | 3.54 | 3.08 | 4.02 | 3.91 | 3.86 | 4.50 | 3.72 | 2.70 | 5.52 | 4.74 | |||||
| Book value | 17.33 | 18.01 | 23.20 | 24.56 | 27.96 | 29.00 | 30.10 | 32.84 | 31.79 | 32.27 | |||||
| Shares, m | 162 | 157 | 153 | 148 | 143 | 140 | 136 | 131 | 127 | 121 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 19.54 | 21.81 | 17.49 | 14.11 | 23.63 | 17.23 | 20.25 | 23.76 | 22.54 | 22.90 | ||||
| P/S | 0.85 | 0.99 | 1.00 | 0.99 | 0.94 | 0.88 | 0.86 | 0.80 | 0.69 | 0.69 | |||||
| P/B | 3.53 | 3.11 | 2.65 | 2.72 | 2.39 | 2.67 | 2.64 | 2.30 | 2.18 | 2.34 | |||||
| EV/Sales | 0.92 | 1.07 | 1.10 | 1.05 | 0.96 | 0.93 | 0.93 | 0.96 | 0.83 | 0.86 | |||||
| EV/FCF | 18.52 | 19.74 | 16.84 | 18.15 | 17.70 | 18.33 | 23.24 | 33.39 | 15.05 | 19.75 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | 643 | 546 | 685 | 654 | 599 | 710 | 602 | 500 | 848 | 712 | ||||
| Capex | (70) | (62) | (71) | (76) | (49) | (79) | (96) | (147) | (148) | (139) | |||||
| Free cash flow | 572 | 483 | 613 | 578 | 550 | 631 | 506 | 353 | 700 | 573 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 1,022 | 1,257 | 956 | 1,188 | 1,508 | 1,537 | 1,764 | 1,805 | 1,180 | 1,236 | ||||
| Total debt | 781 | 924 | 989 | 733 | 626 | 822 | 1,046 | 2,087 | 1,886 | 2,343 | |||||
| Net debt | 719 | 750 | 932 | 627 | 204 | 704 | 929 | 1,916 | 1,764 | 2,187 | |||||
| Shareholders’ equity | 2,801 | 2,824 | 3,542 | 3,630 | 3,984 | 4,063 | 4,095 | 4,289 | 4,031 | 3,899 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | 7.64 | 5.56 | 6.55 | 8.88 | 5.41 | 7.76 | 6.30 | 4.34 | 3.75 | 3.71 | ||||
| ROIC | 13.70 | 11.71 | 8.39 | 10.55 | 7.98 | 11.17 | 9.29 | 6.19 | 6.70 | 6.71 | |||||
| ROE | 17.82 | 14.45 | 16.84 | 19.37 | 10.61 | 15.68 | 13.19 | 9.92 | 9.38 | 10.04 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Henry Schein, Inc. vs peers in Medical Distribution (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MCK McKesson Corporation | $116.4B | 26.8× | 18.3× | +7.72% (above 0%: growing) | −17.68% (below 0%: shrinking) | +66.40% (above 0%: growing) | 3.50% | 1.25% | Compare |
| COR Cencora, Inc. | $65.2B | 25.2× | 14.5× | +5.07% (above 0%: growing) | +11.27% (above 0%: growing) | +3,385.25% (above 0%: growing) | 4.26% | 1.32% | Compare |
| CAH Cardinal Health, Inc. | $58.8B | 35.0× | 23.3× | +5.84% (above 0%: growing) | +68.32% (above 0%: growing) | +10.87% (above 0%: growing) | 4.02% | 1.14% | Compare |
| HSIC Henry Schein, Inc. | $9.7B | 25.0× | 18.5× | +6.73% (above 0%: growing) | +16.90% (above 0%: growing) | +140.91% (above 0%: growing) | 31.84% | 4.95% | |
| AHG Akso Health Group Sponsored ADR | $1.2B | — (loss-making) | — (loss-making) | +263.89% (above 0%: growing) | n/m | −12,975.04% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FOCL FocalTherics | $154.8M | — (loss-making) | — (loss-making) | +38.85% (above 0%: growing) | n/m | +21.49% (above 0%: growing) | 55.59% | (60.83%) | Compare |
| COSM Cosmos Health Inc. | $33.9M | — (loss-making) | 25.1× | +28.76% (above 0%: growing) | n/m | +9.39% (above 0%: growing) | 7.96% | (15.41%) | Compare |
| ACH Accendra Health, Inc. | $20.1M | — (loss-making) | — (loss-making) | −10.07% (below 0%: shrinking) | n/m | −1,624.82% (below 0%: shrinking) | 42.95% | (5.73%) | Compare |
| HKPD Cellyan Biotechnology Co., Ltd | $17.1M | — | — | — | — | −90.45% (below 0%: shrinking) | — | — | Compare |
| Median of peers | $652.4M | 26.8× | 20.8× | +7.72% | +11.27% | +10.13% | 4.26% | 0.00% |
HSIC metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
Henry Schein, Inc. (HSIC) key facts
- Strength: Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024.
- Strength: Net income was $419.0 million, or $3.29 per share (basic), a net margin of 3.02%.
- Henry Schein, Inc. (HSIC) is a Medical Distribution company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, HSIC traded at $86.38, a market capitalization of $9.7 billion.
- At that price the stock trades at 25.0× trailing-twelve-month earnings and 0.7× sales; its P/E is higher than 90% of its own readings over the past ten years.
- Return on equity was 10.0% and debt-to-equity 0.64.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 2.66 (grey zone) for fiscal 2025.